Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and aMVAC in non-urothelial muscle-invasive bladder cancer
NCT04383743Phase 2Completed
- Sponsor
- University of Washington
- Start
- Nov 2020
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Muscle Invasive Bladder Cancer (MIBC), sponsored by University of Washington. Primary endpoint: Pathologic Complete Response Rate. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT04383743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383743.